Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines

Cancer Research

Volumn 56, Issue 12, 1996, Pages 2832-2836

  Chamberlain, Ronald S ^a   Carroll, Miles W ^b   Bronte, Vincenzo ^a   Hwu, Patrick ^a   Warren, Steven ^a   Yang, James C ^a   Nishimura, Michael ^a   Moss, Bernard ^b   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; RECOMBINANT VACCINE; VACCINIA VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLON CARCINOMA; DRUG DESIGN; DRUG EFFICACY; FEMALE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS RECOMBINATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, NEOPLASM; BETA-GALACTOSIDASE; FEMALE; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 9344263997     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. June, C. H., Bluestone, J. A., Nadler, L. M., and Thompson, C B. The B7 and CD28 receptor families Immunol. Today , 15: 321-331, 1994
2. Freeman, G. J., Gray G. S., Gimmi, C. D., Lombard, D. B., Zhou, L. J., White, M., Fingeroth, J. D , Gribben, J. G., and Nadler, L. M. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7 J Exp MeA. 174: 625-631, 1991.
3. Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J. H , Lanier, L. L., and Somoza, C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature (Lond.), 366: 76-79, 1993.
4. Linsley, P. S., Brady, W , Grosmaire, L., Aruffo, A., Damle, N. K., and Ledbetter, J. A Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173: 721-730, 1991.
5. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellstrom, I , and Hellstrom, K E Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity J Exp. Med., 179: 523-532, 1994.
6. Townsend, S. E., and Allison, J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Washington DC), 259. 368-370, 1993
7. Hodge, J. W., Abrams, S., Schlom, J , and Kantor, J. A. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res , 54. 5552-5555, 1994.
8. Hodge, J. W., McLaughlin, J. P , Abrams, S I., Shupert, W. L , Schlom, J , and Kantor, J. A. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res., 55: 3598-3603, 1995.
9. Wang, M., Bronte, V., Chen, P. W., Gritz, L., Panicali, D , Rosenberg, S. A., and Restifo, N P Active immunotherapy of cancer with a non-replicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol., 154: 4685-4692, 1995.
10. Blasco, R., and Moss, B. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene, 158 157-162, 1995.
11. Earl, P. L., and Moss, B. Generation of recombinant vaccinia viruses and their products. In: F. M Ausubel, R. Kinston, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Strahl (eds.), Current Protocols in Molecular Biology, pp. 16.18.1-16.18.10. New York: Greene Publishing Associates and Wiley Interscience, 1991.
12. Smith, G. L., Levin, J. Z., Palese, P., and Moss, B. Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology, 160: 336-345, 1987.
13. Rao, J. B., Chamberlain, R. S., Bronte, V., Carroll, M. W., Irvine, K. R., Moss, B., Rosenberg, S. A., and Restifo, N. P. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines. J. Immunol., 156: 3357-3365, 1996
14. + T lymphocytes in the P815 tumor system in vitro J. Immunol., 156: 465-472, 1996.
15. Yang, G., Hellstrom, K. E., Hellstrom, L. and Chen, L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol., 154: 2794-2800, 1995.
16. Lenschow, D. J., Su, G. H., Zuckerman, L. A., Nabavi, N., Jellis, C. L., Gray, G. S., Miller, J., and Bluestone, J. A. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA, 90: 11054-11058, 1993.
17. L. Immunity, 3: 87-98, 1995.
18. Boon, T., Cerottini, J., Van den Eynde, B., van der Bruggen, P., and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
19. Andrew, M. E., Coupar, B. E., and Boyle, D. B. Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice. Immunol. Cell Biol., 67: 331-337, 1989.
20. Bronte, V., Tsung, K., Rao, J. B., Chen, P. W., Wang, M., Rosenberg, S. A., and Restifo, N. P. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol., 154: 5282-5292, 1995.